Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Miscellaneous and site unspecified neoplasms malignant and unspecified

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44412   clinical trials with a EudraCT protocol, of which   7421   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10 result(s) found for: Miscellaneous and site unspecified neoplasms malignant and unspecified. Displaying page 1 of 1.
    EudraCT Number: 2006-001679-39 Sponsor Protocol Number: 166 Start Date*: 2006-02-16
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: efficacy and safety evaluation of transtec for pain therapy such as first line opioid in patients afected by solid tumors with CT treatment . Fase IV study
    Medical condition: cancer pain refractary to therapy without opioids
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027655 Miscellaneous and site unspecified neoplasms malignant and unspecified HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005718-12 Sponsor Protocol Number: AP26113-11-101 Start Date*: 2012-07-12
    Sponsor Name:ARIAD Pharmaceuticals, Inc.
    Full Title: A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
    Medical condition: Dose Escalation Phase: Histologically confirmed advanced malignancies. All histologies except leukaemia. Dose Expansion Phase: Non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029105 Neoplasms malignant site unspecified NEC HLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10048683 Advanced cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028997 Neoplasm malignant PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027655 Miscellaneous and site unspecified neoplasms malignant and unspecified HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-001409-27 Sponsor Protocol Number: ONC-2006-001 Start Date*: 2006-06-29
    Sponsor Name:ISTITUTO CLINICO HUMANITAS
    Full Title: Pegfilgrastim versus filgrastim after high-dose chemotherapy followed by autologous peripheral blood stem cell, in patients with hematologic and solid tumors a randomized phase II study
    Medical condition: Patients with hematological neoplasia or solid tumors treated with high-dose chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    6.1 10027655 HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000854-85 Sponsor Protocol Number: CA045-020 Start Date*: 2021-04-19
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Phase 1/2 Study of Bempegaldesleukin in Combination with Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Malignancies (PIVOT IO 020)
    Medical condition: Recurrent or Refractory pediatric cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015560 Ewing's sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039022 Rhabdomyosarcoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    20.0 10005329 - Blood and lymphatic system disorders 10025322 Lymphomas non-Hodgkin's unspecified histology HLGT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024329 Leukemia LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065443 Malignant glioma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027107 Medulloblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014967 Ependymoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007958 Central nervous system neoplasm PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended) DE (Completed) IT (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-000004-13 Sponsor Protocol Number: ST200-DM-04-005 Start Date*: 2005-09-16
    Sponsor Name:Sigma-Tau i.f.r. S.p.A.
    Full Title: EVALUATION OF ACETYL -L-CARNITINE (ST 200) TO REDUCE INTENSITY OF TAXANES- OR PLATINUM-INDUCED SENSORY NEUROPATHY
    Medical condition: Peripheral neurophaty in cancer patients previously treated with taxanes- or platinum-based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    7.0 10027655 HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004727-31 Sponsor Protocol Number: IRST100.26 Start Date*: 2016-03-16
    Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS
    Full Title: RANDOMIZED PHASE II TRIAL IN SSTr2 POSITIVE TUMORS TO OPTIMIZE THE INTERVAL BETWEEN CYCLES OF PRRT WITH 177LU DOTATATE (LUTHREE)
    Medical condition: SSTr2 POSITIVE TUMORS
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027655 Miscellaneous and site unspecified neoplasms malignant and unspecified HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-006538-16 Sponsor Protocol Number: A6181114 Start Date*: 2007-03-30
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017, US
    Full Title: AN OPEN-LABEL SUNITINIB MALATE (SU011248) CONTINUATION PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PRIOR SUNITINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO HAVE THE POTENTIAL TO BENEFIT FROM SUNI...
    Medical condition: Malignant Gastrointestinal Stromal Tumor (GIST), Metastatic Breast Cancer, Metastatic Renal Cell Cancer, Pancreatic Neuroendocrine Tumor, Hepatocellular Carcinoma, Prostate Cancer, Thyroid Cancer, ...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027655 Miscellaneous and site unspecified neoplasms malignant and unspecified HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) FR (Completed) DK (Prematurely Ended) GB (Completed) NL (Prematurely Ended) BG (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-001349-14 Sponsor Protocol Number: LEP-ETU-102B Start Date*: 2004-11-18
    Sponsor Name:NeoPharm, Inc.
    Full Title: A Study Extension to Evaluate the Safety and Tolerability of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients that Completed Study LEP-ETU-102A
    Medical condition: advanced non-hematologic malignancies
    Disease: Version SOC Term Classification Code Term Level
    6.1 10027655 HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001093-11 Sponsor Protocol Number: A6181030 Start Date*: 2004-12-24
    Sponsor Name:Pfizer Global Research and Development
    Full Title: A Treatment Protocol for Patients Continuing from a Prior SU011248 Protocol
    Medical condition: This is an open-label treatment protocol for patients who have participated in other SU011248 protocols to completion and are believed to have the potential to derive clinical benefit from SU011248...
    Disease: Version SOC Term Classification Code Term Level
    7.1 10062427 LLY
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Prematurely Ended) NL (Completed) SE (Completed) GR (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002604-17 Sponsor Protocol Number: BAY 43-9006 / 12311 Start Date*: 2009-12-14
    Sponsor Name:Bayer HealthCare AG, D-51368 Leverkusen, Germany
    Full Title: Sorafenib Long Term Extension Program (STEP)
    Medical condition: Various cancer indications/types (e.g. Renal Cell Carcinoma, Hepatoma Carcinoma, Melanoma and other cancer types). Patients who remain actively treated in a Bayer/Onyx sponsored Clinical Trial tha...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028980 Neoplasm LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Completed) IT (Completed) PL (Completed) GB (Completed) BE (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Oct 16 08:38:33 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA